title: Treatment of disorders characterized by reversible airway obstruction in childhood: are anti-cholinergic agents the answer?
abstract: Release of acetylcholine from parasympathetic nerves in the airways activates postjunctional muscarinic receptors present on smooth muscle, submucosal glands and blood vessels. This triggers bronchoconstriction, muscle hypertrophy, mucus secretion, and vasodilatation, respectively. The release of acetylcholine from parasympathetic nerves in lungs is induced by a variety of stimuli and downregulated by the inhibitory activity of neuronal M2 muscarinic receptors via a feedback mechanism. Increased parasympathetic nerve activity occurs in a variety of airway diseases in childhood, including viral-induced wheeze and asthma. Common to these conditions are reversible airway obstruction, mucus hypersecretion, vasodilation and enhanced vascular permeability. In animal models of airway hyperreactivity similar findings of increased acetylcholine release resulting in enhanced supply of this neurotransmitter to the postjunctional smooth muscles, submucosal glands and airway vessels, were demonstrated. While the number and function of postjunctional muscarinic receptors in the airways are unchanged in such airway disorders, inhibitory activity on the parasympathetic nerves appears to be impaired. Specifically, M2 muscarinic receptor dysfunction has been demonstrated in models of bronchial hyperreactivity induced by a variety of triggers, including viruses, atmospheric pollutants and allergens. The mechanisms leading to impairment of neuronal M2 muscarinic receptor function and their putative relevance to the pathogenesis and the treatment of airway disease in childhood are described. Finally, the available data on the activity of ipratropium bromide, a short-acting anticholinergic drug, in the most common pediatric airway disease are reported and the possible therapeutic efficacy of tiotropium bromide, a more recently introduced long-acting, selective anticholinergic compound, is discussed.
authors.affiliation: Division of Pediatric Pulmonology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
authors.forename: Annabelle
authors.initials: A
authors.lastname: Quizon
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Colin
authors.forename: Umberto
authors.initials: U
authors.lastname: Pelosi
authors.forename: Giovanni A
authors.initials: GA
authors.lastname: Rossi
mesh_terms: D000402:Airway Obstruction / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008168:Lung / Q000187:drug effects / Q000294:innervation / Q000503:physiopathology*; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D020239:Receptor Cross-Talk; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000502:physiology
chemical_list: D018680:Cholinergic Antagonists; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic